MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$2,301K
Free Cash flow
$31,015K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Net income
Accrued and other liabilities, c...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Trade receivables
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
42,987
-31,761
24,288
19,668
Stock-based compensation
29,416
23,043
20,768
22,879
Accretion of discount on marketable securities, net
-
-
5,103
-
Accretion of marketable securities, net
-707
3,174
-
-1,005
Depreciation and amortization
863
598
289
289
Deferred income taxes
2,881
-13,110
-15,182
9,114
Amortization of right-of-use asset
-
-
193
188
Trade receivables
37,848
-20,714
-9,843
5,062
Insurance recovery receivable related to melucci litigation (note 10)
-
-
0
0
Inventory
4,264
3,272
-483
3,943
Prepaid expenses and other current assets
3,396
-4,736
3,224
13,461
Other assets
-
-
-2,896
-254
Accounts payable
-18,241
-7,644
5,998
10,921
Accrued research and development expenses
-12,463
137
5,632
-727
Accrued and other liabilities, current and non-current
34,315
-9,377
-13,236
17,158
Accrued settlement related to melucci litigation (note 10)
-
-
0
0
Long-term accrued income taxes
-
-
1,044
48
Operating lease liability
-
-
-251
-247
Net cash provided by operating activities
33,543
-16,772
38,448
54,481
Purchases of property and equipment
2,528
201
50
0
Proceeds from sales and maturities of marketable securities
62,241
57,071
132,040
52,000
Purchases of marketable securities
88,955
52,328
143,833
37,355
Net cash (used in) provided by investing activities
-29,242
4,542
-11,843
14,645
Proceeds from stock option exercises, net of issuance costs
5,757
3,984
2,861
2,033
Proceeds from purchases under the employee stock purchase program
3,663
2,537
2,461
2,170
Repurchases of common stock in connection with stock repurchase program
0
0
0
42,464
Repurchase of common stock in connection with tender offer
-
-
0
-
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants
11,457
5,761
36,538
8,152
Net cash used in financing activities
-2,037
760
-31,216
-46,413
Net effect of exchange rate changes on cash, cash equivalents and restricted cash
37
-287
-32
-320
Net decrease in cash, cash equivalents and restricted cash
2,301
-11,757
-4,643
22,393
Cash, cash equivalents and restricted cash, at beginning of period
109,988
121,745
125,138
127,665
Cash, cash equivalents and restricted cash, at end of period
112,289
109,988
120,495
125,138
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income
$42,987K
(-22.82%↓ Y/Y)
Accrued and other
liabilities, current and...
$34,315K
(571816.67%↑ Y/Y)
Stock-based compensation
$29,416K
(-28.00%↓ Y/Y)
Deferred income taxes
$2,881K
(109.16%↑ Y/Y)
Depreciation and
amortization
$863K
(51.14%↑ Y/Y)
Net cash provided by
operating activities
$33,543K
(-31.64%↓ Y/Y)
Net effect of
exchange rate changes on...
$37K
(-97.94%↓ Y/Y)
Canceled cashflow
$76,919K
Net decrease in
cash, cash...
$2,301K
(109.23%↑ Y/Y)
Canceled cashflow
$31,279K
Trade receivables
$37,848K
(257.36%↑ Y/Y)
Accounts payable
-$18,241K
(-323.84%↓ Y/Y)
Accrued research and
development expenses
-$12,463K
(-158.62%↓ Y/Y)
Inventory
$4,264K
(6.04%↑ Y/Y)
Prepaid expenses and
other current assets
$3,396K
(52.15%↑ Y/Y)
Accretion of marketable
securities, net
-$707K
(76.47%↑ Y/Y)
Proceeds from sales and
maturities of marketable...
$62,241K
(-69.72%↓ Y/Y)
Proceeds from stock
option exercises, net...
$5,757K
(-47.54%↓ Y/Y)
Proceeds from purchases
under the employee...
$3,663K
(-26.59%↓ Y/Y)
Net cash (used in)
provided by investing...
-$29,242K
(-143.67%↓ Y/Y)
Net cash used in
financing activities
-$2,037K
(98.57%↑ Y/Y)
Canceled cashflow
$62,241K
Canceled cashflow
$9,420K
Purchases of marketable
securities
$88,955K
(-35.73%↓ Y/Y)
Cash paid to satisfy
statutory withholding...
$11,457K
(-59.45%↓ Y/Y)
Purchases of property and
equipment
$2,528K
(1470.19%↑ Y/Y)
Buy us a coffee
CORCEPT THERAPEUTICS INC (CORT)
CORCEPT THERAPEUTICS INC (CORT)